Quick Answer
Hepion Pharmaceuticals, Inc. reported Operating Income Loss of -$4.16 million for the year ending 2025.
- Hepion Pharmaceuticals, Inc. showed an increase of +78.5% in Operating Income Loss from 2024 to 2025.
- This data is from Hepion Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2014 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2014 to 2025), Hepion Pharmaceuticals, Inc.'s Operating Income Loss has declined by 149.0%.
- Historical annual values: Fiscal year 2025: -$4.16 million | Fiscal year 2024: -$19.35 million | Fiscal year 2023: -$48.45 million | Fiscal year 2022: -$45.49 million | Fiscal year 2021: -$30.40 million | Fiscal year 2020: -$20.15 million | Fiscal year 2019: -$7.77 million | Fiscal year 2018: -$14.59 million | Fiscal year 2017: -$20.65 million | Fiscal year 2017: -$21.02 million | Fiscal year 2016: -$20.81 million | Fiscal year 2015: -$13.96 million | Fiscal year 2014: -$1.67 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: